Scout | Artificial Intelligence in Pre-clinical Drug Development for AD/ADRD (R01 Clinical Trial Not Allowed)

This opportunity is no longer accepting applications.

grant

Artificial Intelligence in Pre-clinical Drug Development for AD/ADRD (R01 Clinical Trial Not Allowed)

This funding opportunity seeks applications that use artificial intelligence and machine learning (AI/ML) to enhance drug discovery and preclinical drug development for Alzheimer's disease and related dementias. The aim is to speed up the identification and optimization of potential drug candidates, increasing their chances of success in clinical trials. Additionally, the program aims to creat…

Source

Agency: National Institutes of Health

Sub-agency: National Institute on Aging

Award

Total Funding: $1M

Award Ceiling: $1M

Funding Amount: $1M

Dates

Opportunity Released: December 2, 2024

Keywords

Artificial intelligence

machine learning

drug discovery

preclinical drug development

Alzheimer's disease

Alzheimer's-related dementias

open-source analytical tools

academia

biotech

pharma

Supporting Links

Documents

Similar Opportunities

Unlock similar opportunities

Get the full picture on this opportunity

Create a free Scout account to unlock everything you need to decide fast and win the grant.

Instant Fit Analysis

Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
Deep agency & funder detail

Program context, sub-agency structure, and a full eligibility breakdown.
Source links & full documents

Jump straight to the solicitation and download every attachment.
Similar opportunities

Discover related funding matched to your work.

Get a Demo Sign Up

Already have an account? Sign In

Trusted by 500+ Happy Customers